Strategic Partnerships OncoDNA has a history of collaborations with major players like Lilly and SYNLAB, Plus a partner laboratory and distributor network across Europe. This presents opportunities to expand co-development, biomarker testing bundles, and regional expansion through existing channels.

Liquid Biopsy Growth Recent launch of fragmentomics liquid biopsy assay and upcoming OncoXPLORE tumor profiling indicate a strong push into circulating biomarkers and comprehensive profiling. Target customers include clinics and labs seeking non-invasive testing options and broader MRD monitoring.

Theranostic Portfolio Integrated tissue and liquid testing with bioinformatics and reporting tools positions OncoDNA to upsell end-to-end solutions. Potential to sell bundled testing strategies that optimize clinical decision-making and reimbursement alignment.

Global Expansion A Europe-centric network with ambition beyond borders invites partnerships with international laboratories and distributors. Sales opportunities exist in markets needing validated biomarker testing, minimal residual disease monitoring, and therapy selection solutions.

Emerging Analytics Investments in OncoDeep kit and AI-enabled interpretation open doors for selling standardized, scalable sequencing panels and software-driven decision support to oncology centers seeking reproducible biomarker workflows and faster time-to-insight.